2. Immunology/Inflammation
  3. PGE synthase
  4. HPGDS inhibitor 3

HPGDS inhibitor 3 is an orally active and highly potent peripherally restricted hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with IC50 value of 9.4 nM and EC50 of 42 nM, respectively. HPGDS inhibitor 3 exhibits good selectivity, good pharmacokinetic parameters in mouse, rat, and dog, and no CNS toxicity. HPGDS inhibitor 3 has anti-inflammatory activity.

For research use only. We do not sell to patients.

HPGDS inhibitor 3 Chemical Structure

HPGDS inhibitor 3 Chemical Structure

CAS No. : 2255311-93-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

HPGDS inhibitor 3 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

HPGDS inhibitor 3 is an orally active and highly potent peripherally restricted hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with IC50 value of 9.4 nM and EC50 of 42 nM, respectively. HPGDS inhibitor 3 exhibits good selectivity, good pharmacokinetic parameters in mouse, rat, and dog, and no CNS toxicity. HPGDS inhibitor 3 has anti-inflammatory activity[1].

IC50 & Target

IC50: 9.4 nM (H-PGDS)[1]
EC50: 42 nM (H-PGDS)[1]
In Vivo

HPGDS inhibitor 3 (compound 1y) (1-3 mg/kg; PO and IV; single) has a lower IV clearance, similar steady state volume of distribution, longer terminal half-life, and high oral bioavailability, as well as very low brain exposures in mouse, rat and dog[1].
HPGDS inhibitor 3 (0.003-1 mg/kg; PO; single) attenuates PGD2 release to baseline levels in a dose-dependent manner; also inhibits LPS-induced PGD2 increase in plasma and skeletal muscle in a dose-dependent manner[1].
HPGDS inhibitor 3 (0.003-1 mg/kg; PO; single) [1].
HPGDS inhibitor 3 (1, 3, and 10 mg/kg; PO; q.d., for 16 days) significantly enhances functional recovery of injured limbs, and hastens the time to full functional recovery of injured limb muscles[1].
HPGDS inhibitor 3 (10, 30 and 100 mg/kg; PO; once daily, for 7 days or 4 days) exhibits well tolerated at 30 mg/kg/day in rat but not tolerated at 100 mg/kg/day; shows well tolerated at 30 mg/kg/day in dogs but not tolerated at 75 mg/kg/day[1].
Pharmacokinetic Parameters of HPGDS inhibitor 3 in mice, rats and dogs[1].

Mouse
IV, 1 mg/kg
PO, 3 mg/kg		 Rat
IV, 0.4 mg/kg
PO, 2.4 mg/kg		 Dog
IV, 0.5 mg/kg
PO, 1 mg/kg
T1/2 (h) 2.9 5.1 6.2
CL (mL/min/kg) 9.0 4.5 1.9
Vss (L/kg) 1.6 1.6 1.0
F (%) 71 100 92
Brain:blood ratio 0.06

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6J mice (murine mast cell degranulation model of inflammation)[1]
Dosage: 0.003, 0.01, 0.03, 0.1, 0.3 and 1.0 mg/kg
Administration: PO; single (anesthetized 1 hour later, intraperitoneally injected with 0.2 mL PBS or 48/80 (0.75 mg/mL))
Result: Attenuated PGD2 release to baseline levels in a dose-dependent manner with an ED50 of 0.009 mg/kg (blood EC50 = 3.4 nM) in this acute inflammation model.
Animal Model: Male C57BL6/N mice (12 weeks, n=6)[1]
Dosage: 0.003, 0.01, 0.03, 0.1, 0.3 and 1.0 mg/kg
Administration: PO; single (intraperitoneally injection of PBS or 20 ng/kg LPS 1 hour later)
Result: Inhibited LPS-induced PGD2 increase in plasma and skeletal muscle in a dose-dependent manner.
Animal Model: Male C57Bl/6 mice (10-12 weeks, n=7-8; chronic eccentric contraction-induced muscle injury models)[1]
Dosage: 1, 3, and 10 mg/kg
Administration: PO; q.d., for 16 days
Result: Significantly enhanced functional recovery of injured limbs, and significantly hastened the time to full functional recovery of injured limb muscles, with maximal efficacy observed at ≥ 10 mg/kg q.d..
Animal Model: Mdx mouse (6-8 mouths, duchenne muscular dystrophy model)[1]
Dosage: 0.1, 0.3, 1, 3, and 10 mg/kg
Administration: PO; q.d., for 43 days
Result: Significantly improved functional recovery (~90% to 100% restoration), following eccentric contraction-induced muscle injury in mdx mice.
Animal Model: Male Wistar Han rat and dog[1]
Dosage: 10, 30 and 100 mg/kg for rat; 10, 30, and 75 mg/kg for dog
Administration: PO; once daily; for 7 days (rat) or for 4 days (dog)
Result: In rat, the AUC values at 10, 30, and 100 mg/kg/day were 120, 410, and 820 µg•hr/mL, respectively; respective Cmax values were 8.7, 24, and 57 μg/mL. In dog, it showed well tolerated at dose levels up to 30 mg/kg/day with no abnormal microscopic findings; but exhibited discoloration in the small intestine and esophagus (female) at 75 mg/kg/day.
Animal Model: Mice, rats, dongs[1]
Dosage: 1 mg/kg IV and 3 mg/kg p.o in mice, 0.4 mg/kg IV and 2.4 mg/kg PO in rat, 0.5 mg/kg IV and 1 mg/kg PO in dog
Administration: IV and PO; single (Pharmacokinetics Analysis)
Result: Had a lower IV clearance, similar steady state volume of distribution, longer terminal half-life, and high oral bioavailability, as well as very low brain exposures in mouse, rat and dog.
Molecular Weight

353.46

Formula

C21H27N3O2
CAS No.
SMILES

CC(O)([C@H]1CC[C@@H](CC1)NC(C2=CC3=CC=C(N=C3N=C2)C4CC4)=O)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

HPGDS inhibitor 3 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HPGDS inhibitor 32255311-93-2HPGDS inhibitor3HPGDS inhibitor-3PGE synthaseProstaglandin E synthaseOrally activitySelectivityPharmacokineticAnti-inflammatoryInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
HPGDS inhibitor 3
Cat. No.:
HY-146662
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.